Skip to content
Parakho

Unichem Laboratories Ltd

NSE UNICHEMLABBSE 506690

Q1 FY27, unaudited

Revenue
₹632.62 Cr
Profit after tax
₹41.47 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations632.62+20.13%2,201.85
Other income15.61+128.89%63.06
Total income648.23+21.52%2,264.91
Employee benefit expense103.31−3.83%396.63
Finance costs6.62+1.22%31.59
Depreciation & amortisation29.94−5.82%125.12
Total expenses599.24+10.47%2,174.39
Profit before tax48.99+643.13%292.38
Tax expense7.52+418.62%39.54
Profit after tax41.47+496.08%252.84
Total comprehensive income38.41+617.65%264.83
Earnings per share
Earnings per share, basic₹6.61₹35.91
Earnings per share, diluted₹6.61₹35.85

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Unichem Laboratories Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 39 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 26 Sept 2026.